The healthcare realm continues to be confronted by the increasing and daunting prevalence of fungal pathogens, posing significant risks to public health. The expansion of these pathogens, particularly those resistant to treatment, underlines a lack of adequate diagnostics which are rapid, sensitive and broadly accessible. For the infection prevention front line, this poses a serious challenge, predominantly in settings crunched for resources.
Routine fungal infections such as vaginal yeast infections or toenail can be managed adequately. However, more severe instances can prove lethal. The transmission of fungal disease occurs through person-person contact, inhaling spores from infected environments, or sharing clothes.
Two most vulnerable demographics facing invasive fungal infections are patients with grave underlying conditions, such as those struggling with substantial immunocompromised states, and critically ill patients. Others at risk include HIV/AIDS patients, organ transplant recipients, chronic respiratory patients, cancer patients, and those afflicted with tuberculosis.
Among other threats, Candida auris, a multidrug-resistant fungus, has seen a frightening surge globally, triggering massive outbreaks in hospitals. C. auris’ proliferation poses a potent challenge driven by its resistance to several antifungal drugs, high transmissibility, and persistence on surfaces. The key obstacle pertains to the treatment of the C. auris, one of the several species responsible the candida fungus, resulting in infections among humans.
The deadly C.auris can trigger a gamut of serious conditions, like bloodstream, abdomen, throat, or skin infections in susceptible patients. These patients are generally immunocompromised or hospitalized patients. The high mortality rate and widespread resistance to traditionally applied antifungal drugs classify C.auris as a formidable threat in Kenya and globally.
In the face of this, the world is witnessing an upsurge in mortality rates owing to the growing resistance of several strains towards first and secondary-line antifungal treatments. This development has raised complications for clinical management, alongside maintaining infection control measures. Cases of drug-resistant C. auris are escalating at an alarming pace within healthcare setups, making it harder for infection prevention.
An imperative step towards combating the menace of C.auris is enhanced diagnostics and diagnostic infrastructure in hospitals. While minor outbreaks have been identified, many health care establishments lack the infrastructure needed for accurate fungus identification and its resistance to antifungal drugs.
C.Auris has proven to be formidable, becoming resistant to all antifungal classes rendering treatment practically null. Empowering health care setups with necessary resources, trained personnel, and implementing quality assurance measures can significantly aid in containing C.auris.
Streamlined procurement and supply systems are essential to stock requisite medications, and training cleaning staff properly to use specialized disinfectants can help considerably in eliminating C.auris and preventing its transmission.
As this fight continues, the country of Kenya, through its Monitor and Prevent Antimicrobial Resistance (MAP-AMR) fungal surveillance project, serves as a beacon of hope for infection prevention professionals with its model for outbreak preparedness and AMR control in low-resource settings.